0105 areas
Peripheral neuropathy models
ARA-290 has been studied in rodent models of peripheral nerve injury, with researchers examining its interactions with small fiber neuropathy endpoints and nerve conduction parameters.
Optimum ReGen Peptides21+
Research use only
All research products on this site, including all peptides, are sold strictly for laboratory and research use only, not for human or animal consumption, diagnostic, or therapeutic use. Our tallow skincare products are topical cosmetics. You must be 21 or older to enter.
Third-party testedHPLC + MSMedford, OR
By entering you confirm you are 21+ and accept these products are for research use only. See our Terms and Disclaimer.
ARA‑290
For laboratory research. Sold in 10mg and 100mg kit sizes.
$48.00
$6020% off
In stock2-Day Priority Air anywhere in the US
Choose your size
Savings per mg compared with the 10mg size.
1
Secure checkout2-Day Priority AirThird-party tested
Complete the order
Frequently bought together
Supplies and compounds researchers add to this order
Finding add-ons…
Shipping & returns
- 2-Day Priority Air: $13 flat anywhere in the US, or pick up in Medford.
- Tracking is emailed the moment your order ships.
- Research compounds are final sale; see the refund policy.
Lab sheet
ARA-290, measured
Identity, purity and handling data for this compound, in one place. Tap an identifier to copy it.
Certificate of analysis
99.36%
HPLC purity, 10mg lot, reported 07/20/2026
Tested by Freedom Diagnostics, an independent lab. Search code Opti2607170026
View the certificateMolecular Formula
C38H65N11O9
Molar Mass
820.0 g/mol
Form
Lyophilized powder
Full data sheet+
- Purity
- See the available batch report for the tested sample's purity. Confirm the product and lot before ordering.
- Storage (lyophilized)
- -20 °C, protected from light
- Storage (reconstituted)
- 4 °C, use within 7 days
For research use only. Not for human consumption.
Overview
About ARA-290
ARA-290 (also known as Cibinetide) is a synthetic peptide derived from the helical region of erythropoietin (EPO) that is specifically engineered to interact with the innate-repair receptor (IRR) rather than the classical EPO receptor. Researchers designed this compound to separate the tissue-protective properties of EPO from its hematopoietic activity, yielding a molecule studied primarily for its interactions with neural and metabolic pathways in laboratory models.
Read moreShow less
In preclinical research, ARA-290 has been investigated for its role in modulating inflammatory signaling cascades. Studies have explored how the compound engages the beta common receptor subunit in contexts such as peripheral nerve function and pancreatic beta-cell survival. Its selectivity profile makes it a subject of interest in laboratories examining how EPO-derived sequences interact with non-hematopoietic tissues.
As a lyophilized research peptide, ARA-290 is handled under controlled laboratory conditions. Researchers typically reconstitute it in sterile aqueous buffer for in vitro and preclinical in vivo model use. The compound is not intended for human or veterinary clinical use and is supplied exclusively for scientific investigation.
Research context
What ARA-290 is researched for
The areas where this compound appears in the published research literature.
Methodology
How ARA-290 is studied
01Method 1ARA-290 is studied in preclinical animal models and in cell-based assays at nanomolar to low micromolar concentrations.+
ARA-290 is studied in preclinical animal models and in cell-based assays at nanomolar to low micromolar concentrations. Researchers use ELISA-based cytokine profiling, immunohistochemistry of nerve tissue cross-sections, and electrophysiological measurements to characterize downstream effects following compound exposure in relevant animal models.
02Method 2In cell-based assays, ARA-290 is applied to cultured neuronal cell lines, primary Schwann cells, and pancreatic islet preparations to study receptor binding…+
In cell-based assays, ARA-290 is applied to cultured neuronal cell lines, primary Schwann cells, and pancreatic islet preparations to study receptor binding kinetics and intracellular signaling responses including STAT3 and NF-kB pathway modulation. Confocal imaging and Western blot analysis are standard readouts used to quantify pathway engagement.
03Method 3Researchers studying its selectivity profile use receptor binding competition assays comparing ARA-290 to full-length EPO, confirming that the peptide does not…+
Researchers studying its selectivity profile use receptor binding competition assays comparing ARA-290 to full-length EPO, confirming that the peptide does not stimulate erythropoiesis at the concentrations used in tissue-protective studies. This mechanistic separation is a central focus of publications in the field.
Storage protocols
ARA-290 storage and handling
Lyophilized
-20°C
Long-term storage, as supplied
Full handling protocol+
Lyophilized ARA-290 should be stored at -20 °C in a desiccated environment away from direct light. The powder form is stable for extended periods under these conditions. Once reconstituted in sterile aqueous vehicle, the solution should be maintained at 4 °C and used within 5 to 7 days. Repeated freeze-thaw cycles following reconstitution should be avoided to preserve structural integrity.
For long-term laboratory inventory, individual aliquots should be prepared prior to reconstitution to minimize waste and degradation. All handling should be performed in a controlled laboratory environment by trained personnel using appropriate containment practices.
Ordering & shipping
Buy ARA-290 online
ARA-290 (Cibinetide) for sale from Optimum ReGen Peptides, a US research-peptide company with a storefront in Medford, Oregon. It is in stock, priced from $60. Every order ships 2-Day Priority Air, a $13 flat rate anywhere in the US, with tracking, or can be picked up at the store.
The current batch has a published third-party certificate of analysis, shown above. ARA-290 is supplied as lyophilized powder, for laboratory and research use only, not for human consumption.
FAQ
ARA-290 FAQ
What receptor does ARA-290 primarily target in research models?
ARA-290 is designed to interact with the innate-repair receptor (IRR), a heterodimer composed of the EPO receptor and the beta common receptor, rather than with the canonical erythropoietin receptor complex responsible for red blood cell production.
Does ARA-290 stimulate erythropoiesis in laboratory models?
Published preclinical studies indicate that ARA-290 does not produce erythropoietic effects at the concentrations used for tissue-protective investigations, which is a key design feature separating it from full-length EPO.
What solvents are used to reconstitute ARA-290 in research settings?
Researchers typically reconstitute lyophilized ARA-290 in sterile water or phosphate-buffered saline at concentrations appropriate for the specific assay. The solvent choice is determined by the experimental protocol.
How is ARA-290 purity verified for research-grade material?
HPLC and mass spectrometry are analytical methods used to assess peptide purity and identity. Check the available ARA-290 report for the tested sample, recorded methods, and results, and confirm that it applies to the product and lot you are considering.
Is ARA-290 approved for clinical or veterinary use?
No. ARA-290 is supplied exclusively as a laboratory research compound and is not approved for clinical, veterinary, or any other non-research use.
More compounds
Related research compounds
Research library